secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001493152-25-024289
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Q3 revenue $6.8M (+78% seq, +76% YoY); operating loss widens to $4.7M
---------------------------------------------------------------------------

- Revenue of $6.8M in Q3 2025, driven by first full quarter of Sleep Center of Nevada (SCN) acquisition; SCN added $2.2M diagnostic and $1.3M treatment revenue.
- Gross profit $3.9M (58% margin, down from 60% YoY); operating expenses $8.7M (+74% YoY) on SCN-related headcount and depreciation.
- Operating loss $4.7M ($2.6M in Q3 2024); cash $3.1M at Sept 30, 2025 vs $6.3M at Dec 31, 2024.
- Entered management agreement with MISleep Solutions for a joint location in Auburn Hills, MI, seeing patients from December; owns supermajority equity.
- Conference call at 5:00 pm ET; replay available until Dec 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315225024289/0001493152-25-024289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315225024289/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer